# Chemotherapy before the second operation for high-risk incidental gallbladder cancer

Source: https://onco.cc/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/  
OnCo record `idea-gbc-neoadjuvant-for-high-risk-incidental-cancer` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gallbladder cancers found by chance often come back within six months of the second operation, usually far from the gallbladder, which suggests the disease was already in the bloodstream. Two randomised trials are testing chemotherapy first; one closed small, the other reports in 2028.

## Summary

Most recurrences after radical re-resection are distant and early (Varshney 2025). GAIN (Germany, three cycles of gemcitabine-cisplatin before and after surgery) closed in October 2024 with 68 of 333 planned patients; OPT-IN (ECOG-ACRIN, phase 2/3, 186 estimated) randomises T2 to T3 incidental cancer to perioperative or adjuvant chemotherapy with an estimated primary completion of July 2028. Neoadjuvant treatment also selects out patients who progress during chemotherapy and would not have benefited from a major operation. The regimen question has moved on: TOPAZ-1 makes gemcitabine-cisplatin-durvalumab the natural perioperative arm for the next trial.

## Fields

- Kind: Idea
- Last checked: 2026-09-24
- Tags: gallbladder-evidence
- Hypothesis: In T2b, T3 or node-positive incidental gallbladder cancer, three cycles of gemcitabine-cisplatin (with or without durvalumab) before re-resection improves three-year overall survival over re-resection followed by adjuvant therapy.
- Rationale: Early distant recurrence argues for systemic treatment before a morbid operation; the approach is standard in gastric and pancreatic cancer.
- Proposed test: OPT-IN's readout (2028) for chemotherapy alone; a successor trial adding durvalumab to the perioperative arm, stratified by T2a/T2b and nodes, run through the national incidental cancer pathway.
- Maturity: being-tested-at-scale
- Actor: research

## Sources

- Varshney et al.: neoadjuvant treatment for incidental gallbladder cancer, systematic review (Ann Hepatobiliary Pancreat Surg 2025): https://europepmc.org/article/MED/40064481
- ClinicalTrials.gov NCT04559139: https://clinicaltrials.gov/study/NCT04559139
- ClinicalTrials.gov NCT03673072: https://clinicaltrials.gov/study/NCT03673072

## Connected records

- cancers: [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Incidental gallbladder cancer (found after cholecystectomy)](https://onco.cc/cancers/incidental-gallbladder-cancer/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/)
- institutions: [ECOG-ACRIN Cancer Research Group](https://onco.cc/institutions/ecog-acrin/), [Krankenhaus Nordwest / Institute of Clinical Cancer Research (IKF)](https://onco.cc/institutions/krankenhaus-nordwest/)
- terms: [Neoadjuvant / adjuvant / perioperative](https://onco.cc/terms/neoadjuvant-adjuvant/), [Radical (extended) cholecystectomy](https://onco.cc/terms/radical-cholecystectomy/)
- trials: [GAIN (AIO/CALGP/ACO)](https://onco.cc/trials/gain-igbc/), [OPT-IN (EA2197)](https://onco.cc/trials/opt-in/), [TOPAZ-1](https://onco.cc/trials/topaz-1/)
- bottlenecks: [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/), [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)
- key papers: [Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial](https://onco.cc/key-papers/paper-gain-trial-protocol-bmc-cancer-2020/), [Neoadjuvant treatment for incidental gallbladder cancer: A systematic review](https://onco.cc/key-papers/paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer.json